Compare RGEN & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGEN | JHG |
|---|---|---|
| Founded | 1981 | 1934 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.2B |
| IPO Year | N/A | N/A |
| Metric | RGEN | JHG |
|---|---|---|
| Price | $141.49 | $48.27 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 8 |
| Target Price | ★ $177.18 | $47.38 |
| AVG Volume (30 Days) | 680.2K | ★ 1.4M |
| Earning Date | 02-19-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 3.30% |
| EPS Growth | N/A | ★ 104.30 |
| EPS | 0.03 | ★ 5.23 |
| Revenue | $707,890,000.00 | ★ $3,097,300,000.00 |
| Revenue This Year | $17.86 | N/A |
| Revenue Next Year | $12.44 | $7.68 |
| P/E Ratio | $4,604.96 | ★ $9.22 |
| Revenue Growth | 11.74 | ★ 25.23 |
| 52 Week Low | $102.97 | $28.26 |
| 52 Week High | $175.77 | $49.42 |
| Indicator | RGEN | JHG |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 66.80 |
| Support Level | $138.52 | $47.99 |
| Resistance Level | $160.88 | $48.35 |
| Average True Range (ATR) | 7.04 | 0.22 |
| MACD | -2.48 | -0.08 |
| Stochastic Oscillator | 10.87 | 98.73 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Janus Henderson Group provides investment management services to retail intermediary (50% of managed assets), self-directed (20%) and institutional (30%) clients. At the end of September 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $484 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (67%), with customers from Europe, the Middle East, Africa, and Latin America (25%) and the Asia-Pacific region (8%) accounting for the remainder.